BioNTech and Fosun Pharma receive approval to commence COVID-19 Vaccine Candidate BNT162b2 trial in China

▴ BioNTech and Fosun Pharma receive approval to commence COVID-19 Vaccine Candidate BNT162b2 trial in China
BNT162b2 is currently in Phase 3 clinical trials in the United States, Germany, Argentina, Brazil, South Africa, Turkey and other countries

BioNTech SE and Shanghai Fosun Pharmaceutical announced that the China National Medical Products Administration has approved the clinical trial in Mainland China for their mRNA vaccine candidate, BNT162b2.

Wu Yifang, Chairman and CEO of Fosun Pharma, said: “As the ultimate weapon against the COVID-19 pandemic, vaccines will play a vital role in the economic development and social stability of the entire world. I would like to thank the National Medical Products Administration for their great support and for their approval of the clinical trial and we will continue our close collaboration with BioNTech. We are working together and moving forward with the clinical trials and commercialization of mRNA vaccines, to be able to also supply China.”

“This start of the b2 trial in China, in conjunction with the recent interim analysis of the global Phase 3 trial that indicates that our lead candidate may be effective in protecting against COVID-19, is another important step forward,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “Time is of the essence in this effort and we greatly appreciate the support by Chinese regulators and the collaboration with our Chinese partner Fosun Pharma. We will continue to collaborate closely to advance clinical development in China toward market approval.”

BioNTech through its partner Fosun Pharma will now commence a Phase 2 clinical trial in Mainland China. On March 13, 2020, BioNTech and Fosun Pharma announced their strategic collaboration to work jointly on the development and commercialization of potential COVID-19 vaccine products based on BioNTech’s mRNA technology platform in Mainland China, Hong Kong and Macau Special Administration Region, and the Taiwan Region.

BNT162b2 is currently in Phase 3 clinical trials in the United States, Germany, Argentina, Brazil, South Africa, Turkey, and other countries, and received Fast Track designation from the U.S. FDA. In addition, a rolling submission to the European Medicines Agency (EMA) for BNT162b2 has been initiated.

Tags : #BioNTechSE #LatestNewsonBioNTechSE20thNov #FosunPharma #LatestNewsonFosunPharma20thNov #LatestPharmaNews20thNov #LatestNewsonCOVIDVaccine20thNov #LatestPharmaCollaboration20thNov #USFDA #EuropeanMedicinesAgency #MainlandChina

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Scars That Never Heal: The Painful Reality of Female Genital MutilationFebruary 06, 2025
Maharashtra’s Healthcare Betrayal: Why Are Crucial Funds Going Unused?February 06, 2025
1vision, 1 mission: Avaada Foundation’s CSR initiatives are powering communities and delivering sustainable progress across 5 key focus areasFebruary 06, 2025
Top 5 Technology Brands that are Transforming the Cancer Care Journeys for Hospitals and PatientsFebruary 06, 2025
Women's Wellness brand NUA Raises Rs 35 Crore in Pre-Series C led by Mirabilis Investment TrustFebruary 06, 2025
8 Effective Ways to Minimize Postpartum ComplicationsFebruary 06, 2025
Does Where You Live Decide Your Fate? The Urban-Rural Breast Cancer Divide in IndiaFebruary 06, 2025
Nepal leads the world with largest pictorial health warnings on all tobacco productsFebruary 05, 2025
Fleetguard Filters Private Limited Recognized for Excellence in CSR at Navabharat’s 4th CSR ConclaveFebruary 05, 2025
Six new regions of the Russian Federation are set to connect to Moscow's AI medical services platform, MosMedAIFebruary 04, 2025
Six new regions of the Russian Federation are set to connect to Moscow's AI medical services platform, MosMedAIFebruary 04, 2025
Ashok Leyland Reinforces ESG Commitment, Ranked No. 1 Globally in Sustainalytics’ RatingsFebruary 04, 2025
Calcium Supplements: Do You Really Need Them?February 04, 2025
Digital Diagnostics Doubles Its Foreign Publication Count in 2024February 04, 2025
World Cancer Day quotesFebruary 04, 2025
India can take a big leap in Cancer Care with Improved access to treatment and People-centered Approach: ExpertsFebruary 04, 2025
Lilly India appoints Winselow Tucker as the President and General ManagerFebruary 04, 2025
Driving Excellence in Clinical Research: ISCR's 18th Annual Conference Highlights Innovation, Technology, and Patient-CentricityFebruary 04, 2025
Southern Cross University introduces Access25 initiative to make international education more accessible to Indian studentsFebruary 04, 2025
Why Millions Suffer from Ineffective Treatments And the New Science That Can Save ThemFebruary 04, 2025